

**4<sup>th</sup> Edition**  
**Revised Reprint**

# ESSENTIALS OF MEDICAL MICROBIOLOGY

**with Complimentary Questions**

**As per the Revised Competency-based Medical Education**

**Apurba S Sastry**  
**Sandhya Bhat**



**Genuine?**  
Scratch, Scan  
& Validate



**ONE STOP RESOURCE  
FOR ALL YOUR EXAM NEEDS IN  
MICROBIOLOGY**

**Complementary to Essentials of Medical Microbiology, 4/e**

**Question Bank as per NMC-recommended CBME Curriculum for MBBS**

Reasoning type questions • Long and short answer questions  
Case scenario-based questions • MCQs (direct and case based)

**Apurba S Sastry**  
**Sandhya Bhat**  
**Anand Bhimaray Janagond**



# Contents

	Competency Number (NMC Curriculum)	Pages
<b>PART I: General Microbiology, Immunology and Hospital Infection Control</b>		
<b>Section 1: General Microbiology</b>		
1. Introduction and History	MI 1.1	3
2. Microscopy	MI 1.4	6
3. General Bacteriology		
3.1. Bacterial Taxonomy	MI 1.2	11
3.2. Morphology and Physiology of Bacteria	MI 1.2	14
3.3. Laboratory Diagnosis of Bacterial Infections	MI 1.3 to 1.10, 9.3, 11.1	22
• Specimen Collection	MI 1.5, 1.7	
• Direct Detection (Staining Methods and Others)	MI 1.4, 1.10	
• Culture, Identification and Antimicrobial Susceptibility Test	MI 1.4, 11.1	
• Molecular Diagnosis and Typing Methods	MI 1.3	
3.4. Bacterial Genetics	MI 1.3	43
3.5. Antimicrobial Agents and Antimicrobial Resistance	MI 11.1, 11.2, 10.5	51
3.6. Pathogenesis of Bacterial Infections	MI 1.1, 1.2	58
3.7. Overview of Bacterial Infections	MI 1.1, 1.2	62
4. General Virology and Overview of Viral Infections	MI 1.1, 1.2, 1.4 to 1.6	70
5. General Parasitology and Overview of Parasitic Infections	MI 1.1, 1.2, 1.4 to 1.6, 1.10	89
6. General Mycology and Overview of Fungal Infections	MI 1.1, 1.2, 1.4 to 1.6	101
7. Normal Human Microbiota	MI 1.1	107
8. Epidemiology of Infectious Diseases	MI 1.11	111
<b>Section 2: Immunology</b>		
9. Immunity (Innate and Acquired)	MI 2.1	119
10. Antigen	MI 2.2	125
11. Antibody	MI 2.2	129
12. Antigen-antibody Reaction	MI 2.5	136
13. Complement	MI 2.2	146
14. Components of Immune System: Organs, Cells and Products	MI 2.2	152
15. Immune Responses: Cell-mediated and Antibody-mediated	MI 2.3, 2.4	166
16. Hypersensitivity	MI 2.7	174
17. Autoimmunity	MI 2.7	182
18. Immunodeficiency Disorders	MI 2.7	185
19. Transplant and Cancer Immunology	MI 2.8	189
20. Immunoprophylaxis	MI 2.6	195
<b>Section 3: Hospital Infection Control</b>		
21. Healthcare-associated Infections	MI 10.1, 10.2, 10.3, 10.5	203
22. Major Healthcare-associated Infection Types	MI 10.1, 10.2	213
23. Sterilization and Disinfection	MI 1.12, 1.13	220

24. Biomedical Waste Management	MI 10.3	<b>232</b>
25. Needle Stick Injury	MI 10.2	<b>237</b>
26. Antimicrobial Stewardship	MI 11.3	<b>241</b>
27. Environmental Surveillance (Bacteriology of Water, Air and Surface)	MI 10.4	<b>245</b>

## **PART II: SYSTEMIC MICROBIOLOGY (INFECTIOUS DISEASES)**

### **Section 4: Bloodstream and Cardiovascular System Infections**

28. Cardiovascular System Infections: Infective Endocarditis and Acute Rheumatic Fever	MI 3.1 to 3.4, 3.9, 3.10	<b>251</b>
29. Bloodstream Infections (Including Infections Causing Anemia)	MI 3.3, 3.5, 3.9	<b>257</b>

#### **Bacterial Infections**

30. Enteric Fever ( <i>Salmonella</i> Typhi and <i>Salmonella</i> Paratyphi)	MI 3.6, 3.7, 3.8	<b>262</b>
31. Rickettsial Infections	MI 1.1, 1.6	<b>269</b>
32. Miscellaneous Bacterial Bloodstream Infections: Brucellosis, Leptospirosis and Borreliosis	MI 1.1, 1.6, 9.1	<b>275</b>

#### **Viral Infections**

33. HIV/AIDS	MI 3.13, 1.9	<b>283</b>
34. Viral Hemorrhagic Fever (VHF) Arboviral VHF (Dengue, Chikungunya and Others), Filoviral VHF (Ebola and Marburg Virus), Hantaviral and Other Agents of VHF	MI 1.1, 1.6	<b>293</b>

#### **Parasitic Infections**

35. Malaria and Babesiosis	MI 3.10, 3.11, 3.12	<b>303</b>
36. Visceral Leishmaniasis and Trypanosomiasis	MI 3.11	<b>311</b>
37. Lymphatic Filariasis	MI 3.10, 3.11	<b>316</b>

#### **Fungal Infections**

38. Systemic Candidiasis and Systemic Mycoses	MI 1.1, 1.6	<b>321</b>
---	-------------	------------

### **Section 5: Gastrointestinal (GI) Infections**

39. Gastrointestinal Infective Syndromes	MI 4.1	<b>327</b>
--	--------	------------

#### **Bacterial Infections**

40. Food Poisoning: <i>S. aureus</i> , <i>Bacillus cereus</i> , <i>Clostridium botulinum</i> and Others	MI 4.1, 4.5	<b>332</b>
41. Gastrointestinal Infections due to Enterobacteriales: Diarrheagenic <i>Escherichia coli</i> , Shigellosis, Nontyphoidal Salmonellosis and Yersiniosis	MI 4.1 to 4.4	<b>337</b>
42. Cholera, Halophilic <i>Vibrio</i> and <i>Aeromonas</i> Infections	MI 4.1, 4.2, 4.4	<b>346</b>
43. Miscellaneous Bacterial Infections of Gastrointestinal System: <i>Helicobacter</i> , <i>Campylobacter</i> and <i>Clostridioides difficile</i> Infections	MI 4.1, 4.2, 4.4, 4.6	<b>354</b>

#### **Viral Infections**

44. Viral Gastroenteritis: Rotaviruses and Others	MI 4.1, 4.2, 4.4	<b>359</b>
---	------------------	------------

#### **Parasitic Infections**

45. Intestinal Protozoan and Fungal Infections: Intestinal Amoebiasis, Giardiasis, Coccidian Parasitic Infections, Balantidiasis, Blastocystosis, and Others	MI 4.1 to 4.4	<b>362</b>
46. Intestinal Helminthic Infections	MI 4.1 to 4.4, 3.10	<b>374</b>
• Intestinal Cestode Infections: <i>Diphyllobothrium</i> , <i>Taenia</i> , <i>Hymenolepis</i> and Others		
• Intestinal Trematode Infections: <i>Fasciolopsis buski</i> , <i>Schistosoma mansoni</i> , <i>S. japonicum</i> and Others		
• Intestinal Nematode Infections: <i>Trichuris</i> , <i>Enterobius</i> , hookworm, <i>Strongyloides</i> , <i>Ascaris</i> and Others		

### **Section 6: Hepatobiliary System Infections**

47. Infective Syndromes of Hepatobiliary System and Abdomen	MI 1.1, 4.1	<b>393</b>
---	-------------	------------

#### **Viral Infections**

48. Viruses Causing Hepatitis Hepatitis Viruses, Yellow Fever and Others	MI 4.7, 4.8, 4.9	<b>395</b>
---	------------------	------------

**Parasitic Infections**

49. Parasitic Infections of Hepatobiliary System MI 1.1, 4.1, 9.1 **409**  
 Amoebic Liver Abscess, Hydatid Disease (*Echinococcus*), Trematode Infections  
 (*Fasciola hepatica*, *Clonorchis* and *Opisthorchis*) and Others

**Section 7: Skin, Soft Tissue and Musculoskeletal System Infections**

50. Infective Syndromes of Skin, Soft Tissue and Musculoskeletal Systems MI 5.1, 5.2, 5.3, 5.4, 5.5 **417**

**Bacterial Infections**

51. Staphylococcal Infections MI 5.2, 5.3 **422**  
 52. Beta-hemolytic Streptococcal Infections MI 5.2, 5.3 **430**  
 53. Gas Gangrene (*Clostridium perfringens*) and Infections due to Non-sporing Anaerobes MI 5.1 **437**  
 54. Leprosy (*Mycobacterium leprae*) MI 5.5 **444**  
 55. Miscellaneous Bacterial Infections of Skin and Soft Tissues: MI 5.2, 5.3, 5.5 **449**  
 Anthrax (*Bacillus anthracis*), Actinomycosis, Nocardiosis, Nonvenereal Treponematoses  
 and Others

**Viral Infections**

56. Viral Exanthems and Other Cutaneous Viral Infections MI 5.2, 5.3, 5.4 **459**  
 Herpesviruses (Herpes Simplex, Varicella-zoster and HHV-6 and 7 Infection),  
 Poxviruses (Smallpox, Molluscum contagiosum), Parvovirus, Measles, Rubella,  
 Coxsackieviruses and Others

**Parasitic Infections**

57. Parasitic Infections of Skin, Soft Tissue and Musculoskeletal System MI 5.2, 5.3 **474**  
 Cutaneous Leishmaniasis, Cysticercosis, Tissue Nematodes (Filarial Tissue Nematodes,  
*Dracunculus medinensis*, *Trichinella spiralis*) and Larva Migrans

**Fungal Infections**

58. Fungal Infections of Skin, Soft Tissue and Musculoskeletal System MI 5.2, 5.3 **478**  
 Superficial Fungal Infections, Subcutaneous Fungal Infections, Candidiasis (cutaneous  
 and mucosal) and *Penicillium marneffei* Infection

**Section 8: Respiratory Tract Infections**

59. Infective Syndromes of Respiratory Tract MI 7.1, 7.2, 7.3 **487**

**Bacterial Infections**

60. Bacterial Pharyngitis: *Streptococcus pyogenes* Pharyngitis, Diphtheria and Others MI 7.1, 7.4 **491**  
 61. Bacterial Lobar Pneumonia: Pneumococcal Pneumonia, *Haemophilus influenzae* MI 7.2, 7.3, 7.5 **499**  
 Pneumonia and Others  
 62. Bacterial Atypical (Interstitial) Pneumonia: *Mycoplasma*, *Chlamydia*, *Legionella* and MI 7.2, 7.3, 7.5 **510**  
 Others  
 63. Tuberculosis and Nontuberculous Mycobacteria Infections MI 7.2, 7.5 **515**  
 64. Pertussis (*Bordetella pertussis*) MI 7.2, 7.5 **530**  
 65. Infections due to Non-fermenting Gram-negative Bacilli: *Pseudomonas*, *Acinetobacter*, MI 7.2, 7.5 **534**  
*Burkholderia* and Others

**Viral Infections**

66. Myxovirus Infections of Respiratory Tract: Influenza, Parainfluenza, Mumps, MI 7.1 to 7.5 **540**  
 Respiratory Syncytial Virus and Others  
 67. Coronavirus Infections Including COVID-19 MI 7.1 to 7.5 **551**  
 68. Miscellaneous Viral Infections of Respiratory Tract: Rhinovirus, Adenovirus and MI 7.1, 7.4 **557**  
 Infectious Mononucleosis (Epstein-Barr Virus)

**Parasitic and Fungal Agents**

69. Parasitic and Fungal Infections of Respiratory Tract MI 7.1 to 7.5 **561**  
 • Parasitic Infections: Paragonimiasis and Others  
 • Fungal Infections: Zygomycosis, Aspergillosis, Pneumocystosis and Others

**Section 9: Central Nervous System Infections**

70. Infective Syndromes of Central Nervous System MI 6.1 to 6.3 **571**



**Bacterial Infections**

- |   |             |            |
|---|-------------|------------|
| 71. Bacterial Meningitis  | MI 6.1, 6.3 | <b>574</b> |
| <ul style="list-style-type: none"> <li>• Acute Bacterial (Pyogenic) Meningitis: <i>Neisseria meningitidis</i>, <i>Streptococcus pneumoniae</i>, <i>Streptococcus agalactiae</i>, <i>Haemophilus influenzae</i> and <i>Listeria</i></li> <li>• Chronic Bacterial Meningitis: Tubercular Meningitis, Spirochetal Meningitis, Lyme Disease and Others</li> </ul> |             |            |
| 72. Tetanus   | MI 5.1      | <b>584</b> |

**Viral Infections**

- |  |             |            |
|--|-------------|------------|
| 73. Viral Meningitis and Myelitis: Poliomyelitis, Coxsackievirus Infections, and Others  | MI 6.1, 6.3 | <b>588</b> |
| 74. Viral Encephalitis and Encephalopathy<br>Rabies, HSV Encephalitis, Arboviral Encephalitis (Japanese Encephalitis and West Nile),<br>Nipah and Hendra, Slow Virus and Prion Disease, and Others | MI 6.2      | <b>597</b> |

**Parasitic and Fungal Infections**

- |  |                  |            |
|--|------------------|------------|
| 75. Parasitic and Fungal Infections of Central Nervous System  | MI 6.1, 6.2, 6.3 | <b>609</b> |
| <ul style="list-style-type: none"> <li>• Parasitic Infections: Neurocysticercosis, Free-living Amoeba Infections, Toxoplasmosis and Others</li> <li>• Fungal Infections: Cryptococcal Meningitis and Others</li> </ul> |                  |            |

**Section 10: Urogenital Tract Infections**

- |  |                  |            |
|--|------------------|------------|
| 76. Infective Syndromes of Urinary Tract   | MI 8.1, 8.4      | <b>621</b> |
| <ul style="list-style-type: none"> <li>• Bacterial Infections: Enterobacterales, <i>Enterococcus</i> and Others</li> <li>• Viral (BK Virus), Parasitic (<i>Schistosoma haematobium</i>) and Fungal Infections</li> </ul>   |                  |            |
| 77. Infective Syndromes of Genital Tract and Sexually-transmitted Infections   | MI 8.1, 8.2, 8.3 | <b>631</b> |
| <ul style="list-style-type: none"> <li>• Ulcerative Genital Disease: Syphilis, Lymphogranuloma Venerum, Granuloma Inguinale, Soft Chancre and Genital Herpes</li> <li>• Gonorrhea and Non-gonococcal Urethritis (<i>Chlamydia trachomatis</i> and Others)</li> <li>• Vulvovaginitis (Trichomoniasis, Bacterial Vaginosis, Vaginal Candidiasis)</li> <li>• Other Genital Tract Infections of Females and Males</li> </ul> |                  |            |

**Section 11: Miscellaneous Infective Syndromes**

- |  |                  |            |
|--|------------------|------------|
| 78. Ocular and Ear Infections  | MI 1.2, 1.4, 1.5 | <b>653</b> |
| 79. Congenital Infections<br>Cytomegalovirus Infections, Congenital Varicella, Neonatal Herpes, Congenital Rubella,<br>Congenital Toxoplasmosis, Congenital Syphilis, Zika Virus Infections and Others | MI 1.2, 1.4, 1.5 | <b>659</b> |
| 80. Organisms with Oncogenic Potential<br>Human Papilloma Virus, Kaposi Sarcoma, HTLV and HIV, Epstein-Barr Virus,<br>Hepatitis B and C, and Others  | MI 9.4           | <b>665</b> |
| 81. Zoonotic Infections: Plague, Tularaemia and Bite Wound Infections  | MI 9.1           | <b>671</b> |

**Annexures**

- |  |                                     |            |
|--|-------------------------------------|------------|
| 1. Opportunistic Infections                              | MI 9.2                              | <b>681</b> |
| 2. Post-transplantation Infections                       | MI 9.2                              | <b>682</b> |
| 3. Emerging and Re-emerging Infections                   | MI 9.5                              | <b>683</b> |
| 4. Bioterrorism—Biological Warfare                       | MI 1.1                              | <b>684</b> |
| 5. Laboratory-acquired Infections                        | MI 1.1                              | <b>686</b> |
| 6. National Health Programmes for Communicable Diseases  | MI 9.6                              | <b>687</b> |
| 7. Vector-borne Infections and Ectoparasite Infestations | MI 8.1                              | <b>688</b> |
| 8. Transfusion-transmitted Infections                    | MI 1.1                              | <b>691</b> |
| 9. AETCOM in Microbiology                                | MI 1.7, 1.8, 1.9                    | <b>692</b> |
| 10. Pandemic Management                                  | NMC's Pandemic<br>Management Module | <b>701</b> |

# PART II

## Systemic Microbiology (Infectious Diseases)

**Section 4:** Bloodstream and Cardiovascular System Infections

**Section 5:** Gastrointestinal Infections

**Section 6:** Hepatobiliary System Infections

**Section 7:** Skin, Soft Tissue and Musculoskeletal System Infections

**Section 8:** Respiratory Tract Infections

**Section 9:** Central Nervous System Infections

**Section 10:** Urogenital Tract Infections



**Section 11:** Miscellaneous Infective Syndromes

### Bloodstream and Cardiovascular System Infections

## 4 SECTION

#### SECTION OUTLINE

28. Cardiovascular System Infections
29. Bloodstream Infections (Including Infections Causing Anemia)
30. Enteric Fever (*Salmonella Typhi* and *Salmonella Paratyphi*)
31. Rickettsial Infections
32. Miscellaneous Bacterial Bloodstream Infections: Brucellosis, Leptospirosis and Borreliosis
33. HIV/AIDS
34. Viral Hemorrhagic Fever  
Arboviral VHF (Dengue, Chikungunya and Others), Filoviral VHF (Ebola and Marburg Virus), Hantaviral and Other Agents of VHF
35. Malaria and Babesiosis
36. Visceral Leishmaniasis and Trypanosomiasis
37. Lymphatic Filariasis
38. Systemic Candidiasis and Systemic Mycoses





# ANTIBIOTIC GUARDIAN

*If we use antibiotics when not needed,  
we may not have them when they are most needed*



# Cardiovascular System Infections

## CHAPTER 28

### CHAPTER PREVIEW

■ Infective Endocarditis

■ Other Infections of CVS

■ Acute Rheumatic Fever

### INTRODUCTION

Cardiovascular system infections include infections of heart and blood vessels.

- ❖ **Infections of heart:** This includes infection of the three layers of the heart wall
  - Infection of the endocardium—called *infective endocarditis*
  - Infection of the myocardium—known as *myocarditis*
  - Infection of the pericardium—called *pericarditis*. Collection of excess fluid in pericardial cavity is called pericardial effusion.
- ❖ **Infections of blood vessels:** Infections of blood vessels include mycotic aneurysm, and infective endarteritis
- ❖ **Device-related infections:** These include CRBSI (catheter-related bloodstream infection) and suppurative thrombophlebitis
- ❖ **Autoimmune-mediated:** Acute rheumatic fever.

### INFECTIVE ENDOCARDITIS

Infective endocarditis (IE) refers to microbial invasion of the heart valves or mural endocardium—characteristically results in formation of bulky friable *vegetations*, composed of mass of platelets, fibrin, microcolonies of organisms, and scanty inflammatory cells.

Vegetations are most commonly present on the heart valves, followed by the low-pressure side of a ventricular septal defect, and on the mural endocardium.

#### Classification

Infective endocarditis can be classified into acute and subacute forms based on rapidity of evolution, severity of infection and virulence of the implicated organism (Table 28.1).

#### Pathogenesis of IE

The pathogenesis of IE involves the following sequential steps.

- ❖ **Predisposing factors:** There are several factors that can attribute the pathogenesis of IE—(i) underlying cardiac defect (e.g. mitral regurgitation), (ii) use of intravenous catheter, (iii) prosthetic valve surgery

**Table 28.1: Differences between acute and subacute endocarditis.**

Acute endocarditis	Subacute endocarditis
Evolution is rapid	Evolution is slow
Involves normal cardiac valve	Involves previously damaged heart (scarred or deformed valve)
Implicated organism is of high virulence, e.g. <i>S. aureus</i>	Implicated organism is of low virulence, e.g. viridans streptococci
Causes substantial morbidity and mortality even with the appropriate antibiotic therapy and/or surgery	Follows a gradually progressive course of weeks to months; most patients recover after antibiotic therapy
Less common type, accounts for 10–20% of all cases	More common type, accounts for 50–60% of all cases

- ❖ **Endothelial injury:** Predisposing factors produce damage to the endothelial surface of the heart, which favors deposition of platelets and fibrin, resulting in thrombus formation—a condition called *nonbacterial thrombotic endocarditis (NBTE)*
- ❖ **Colonization:** During transient bacteremia (e.g. after brushing the teeth), the bacteria adhere to the thrombus
- ❖ **Formation of vegetations:** After colonization, further deposition of platelets, fibrin, and inflammatory cells occurs surrounding the entrapped organisms—to produce **vegetation** (Fig. 28.1)
- ❖ **Metastasis:** The resulting vegetations ultimately seed bacteria into the blood at a slow but constant rate, which can metastasize to distant sites.

#### Etiological Agents of IE


The causative organisms of IE differ depending on the underlying risk factors such as native or prosthetic valve IE, acute or subacute IE, other risk factors such as IV drug abuser (Table 28.2).

#### Clinical Manifestations

The clinical spectrum of IE includes both cardiac and noncardiac manifestations.

- ❖ **Cardiac manifestations** include the appearance of a new/worsened regurgitant murmur, which is more useful for the diagnosis of IE involving a normal valve





**Fig. 28.1:** Subacute bacterial endocarditis involving mitral valve showing large vegetations on valve leaflets.

Source: Public Health Image Library, ID # 851 (Dr Edwin)/ Centers for Disease Control and Prevention (CDC), Atlanta (with permission).

- ❖ **Noncardiac manifestations** include fever, chills and sweats, anorexia, weight loss, myalgia, arthralgia, arterial emboli, splenomegaly, clubbing, petechiae, neurologic manifestations and peripheral manifestations (Osler's nodes, subungual hemorrhages, Janeway lesions)
- ❖ **Laboratory findings** such as anemia, leucocytosis, microscopic hematuria, elevated ESR, CRP, or rheumatoid factor.

### Diagnosis (Modified Duke Criteria)

The diagnosis of IE is established with the help of a highly sensitive and specific diagnostic schema—known as the **modified Duke criteria**; which is based on clinical, laboratory, and echocardiographic findings (Table 28.3).

### Blood Cultures

Isolation of the causative microorganism from blood cultures is critical for diagnosis, determination of antimicrobial susceptibility, and planning of treatment. Blood cultures should be collected before antibiotic therapy.

- ❖ Two blood culture sets should be collected at an interval of >12hr between 1<sup>st</sup> and 2<sup>nd</sup> set
- ❖ Alternatively, three or more blood culture sets can be collected over ≥1 hour (e.g. 30 min gap between 1<sup>st</sup> and 2<sup>nd</sup> set and 30 min gap between 2<sup>nd</sup> and 3<sup>rd</sup> set).

**Note:** Blood culture set refers to blood collected from single venipuncture site and divided into two bottles. It is considered as positive if any of the bottle flags positive.

**A major criterion** can be fulfilled (Table 28.3), if:

- ❖ A typical IE organism is isolated from two separate blood cultures, or
- ❖ Agent other than typical IE organisms is isolated persistently from blood cultures in the absence of an extra-cardiac focus of infection.

**A minor criterion** is considered to be fulfilled (Table 28.3) if blood cultures show positive but not meeting major criterion.

Blood culture collection technique and processing is discussed in detail in Chapter 29.

**Table 28.2:** Agents of infective endocarditis.

#### Etiological agents of infective endocarditis

- *Staphylococcus aureus*
- Coagulase-negative staphylococci (e.g. *S. epidermidis*)
- Streptococci (Viridans streptococci and others)
- Enterococci (refer Chapter 76 for details)
- Pneumococci
- Fastidious gram-negative coccobacilli (HACEK group)
- Enterobacteriaceae
- *Pseudomonas* spp. (usually in drug users)
- *Candida* species
- Diphtheroids

#### Most common agent in specific types of endocarditis

**Native valve endocarditis:** *Staphylococcus aureus*

- Community acquired—Viridans streptococci
- Healthcare associated—*S. aureus*
- Overall—*S. aureus*

**Prosthetic valve endocarditis (PVE):** It occurs following cardiac valve replacement:

- **Early PVE** (occurs within 12 months of surgery)—CoNS (e.g. *S. epidermidis*) and *S. aureus* are the most common agents
- **Late PVE** (occurs after 12 months)—viridans streptococci are the most common agent
- **Overall**—Regardless of the time of onset, CoNS are the most common agent, and the majority are methicillin resistant.

**IE in IV drug abusers:** Young males are the most common victims. The skin is the commonest source of infection.

- **Right-sided IE (tricuspid valve)**—*S. aureus* is the most common agent, majority are MRSA
- **Left-sided IE (mitral valve)**—more varied etiology, including Enterobacterales, *Pseudomonas aeruginosa*, *Candida*, etc.
- **Overall**—Most common agent is *S. aureus*

**Subacute endocarditis:** Viridans streptococci

#### Culture-negative endocarditis:

About 5–10% of IE have negative blood cultures; majority (one-third to one-half) of which are because of prior antibiotic exposure. The remainder of these patients are infected by fastidious organisms, such as:

- Nutritionally variant streptococci (*Granulicatella* and *Abiotrophia*)
- HACEK organisms—HACEK organisms

Others: *Coxiella burnetii*, *Bartonella* species, *Brucella* species, *Tropheryma whippelii*

**Note:** Majority of *S. aureus* causing IE are methicillin resistant *S. aureus* (MRSA).

**Abbreviations:** HACEK, *Haemophilus* species, *Aggregatibacter* species, *Cardiobacterium hominis*, *Eikenella corrodens*, and *Kingella kingae*; CoNS, coagulase-negative staphylococci.

### Non-blood-culture Tests

Various non-blood-culture tests that can be used for the diagnosis of IE include:

- ❖ Serologic tests can be used to implicate some organisms that are difficult to recover by blood culture: *Brucella*, *Bartonella*, *Legionella*, *Chlamydia psittaci*, and *Coxiella burnetii*
- ❖ Isolation of the pathogens in vegetations by culture
- ❖ Microscopic examination with special stains (e.g. periodic acid–Schiff stain for *Tropheryma whippelii*)
- ❖ Direct fluorescence antibody techniques
- ❖ PCR to recover unique microbial DNA or 16S rRNA that, when sequenced, allows identification of the etiologic agent.

**Table 28.3: Modified Duke criteria for the clinical diagnosis of infective endocarditis.****Major Criteria**

- 1. Positive blood culture:** Any one of the following:
  - A. Typical IE organism isolated from two separate blood culture sets (Viridans streptococci, *Streptococcus gallolyticus*, HACEK group, *S. aureus* or enterococci) or
  - B. Persistently positive blood culture with agents other than typical IE organisms:
    - At least two blood culture sets drawn >12 h apart; or
    - All of 3 sets or a majority of ≥4 separate blood culture sets, with first and last drawn at least 1 h apart
  - C. Single positive blood culture for *Coxiella burnetii* or phase I IgG antibody titer of >1:800
- 2. Evidence of endocardial involvement:** Any one
  - A. Positive echocardiogram
    - Oscillating intracardiac mass on valve or
    - Abscess, or
    - New partial dehiscence of prosthetic valve
  - B. New valvular regurgitation

**Minor Criteria**

- 1. Predisposition:** Predisposing heart conditions or IV drug use
- 2. Fever** ≥ 38.0°C (≥100.4°F)
- 3. Vascular phenomena:** Major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages or Janeway lesions
- 4. Immunologic phenomena:** Glomerulonephritis, Osler's nodes, Roth's spots or rheumatoid factor
- 5. Microbiologic evidence:** Positive blood culture but not meeting major criterion as noted previously<sup>a</sup> or serologic evidence of active infection with organism consistent with infective endocarditis

**Definite endocarditis** if the followings are present:

- Two major criteria or
- One major criterion and three minor criteria or
- Five minor criteria

<sup>a</sup>Excluding single positive blood cultures for coagulase-negative staphylococci and diphtheroids, which are common culture contaminants, and organisms that do not cause endocarditis frequently, such as gram-negative bacilli.

Abbreviation: IE, infective endocarditis.

**Echocardiography**

Echocardiography allows anatomic confirmation of infective endocarditis, sizing of vegetations, detection of intracardiac complications, and assessment of cardiac function.

**TREATMENT****Infective endocarditis****1. Regimen for *S. aureus* IE****For native valve IE:**

- ❑ **For MSSA** (methicillin susceptible *S. aureus*): Cloxacillin or nafcillin is given for 6 weeks
- ❑ **For MRSA** (methicillin resistant *S. aureus*): Vancomycin is given for 6 weeks

**For prosthetic valve IE:**

In addition to above regimen, rifampin (for 6 weeks) and gentamicin (for 2 weeks) are added.

**2. Regimen for viridans streptococci and *S. gallolyticus* IE**

- ❑ For native valve IE: Penicillin or ceftriaxone is given for 4 weeks
- ❑ For prosthetic valve IE: Gentamicin is added to the above regimen for 6 weeks

**3. For HACEK endocarditis**

Ceftriaxone or ciprofloxacin is given for 4 weeks. Treatment may be extended for 6 weeks in case of prosthetic valve IE.

**Agents Causing IE**

Infective endocarditis due to staphylococci, Viridans streptococci, nutritionally variant streptococci, and HACEK group of pathogens are discussed in this chapter. The other etiological agents of IE are discussed under different systems they principally infect.

**Staphylococcal Endocarditis**

*S. aureus* is the most common cause of IE; usually runs an acute course.

- ❖ *S. aureus* IE presents with larger vegetations (>10 mm in diameter), and therefore is more frequently associated with features of septic embolization (due to breaking of vegetations leading to formation of emboli) such as subungual hemorrhage, Osler's nodes, etc.
  - Cerebrovascular emboli can cause stroke or occasionally encephalopathy
  - Embolization risk is higher for mitral valve IE.
- ❖ *S. aureus* appears gram-positive cocci arranged in cluster, produces golden yellow hemolytic colonies on blood agar and gives a positive coagulase test (refer to Chapter 51)
- ❖ Coagulase-negative staphylococci (e.g. *S. epidermidis*) are increasingly associated with prosthetic valve endocarditis (at least 68–85% of cases) and majority of them are methicillin resistant.

Staphylococci can cause infections of various other systems such as skin and soft tissue (refer to Chapter 51 for details).

**Viridans Streptococci**


Viridans streptococci are commensals of mouth and upper respiratory tract. Usually, they are nonpathogenic, however occasionally cause diseases such as:

- ❖ **Subacute bacterial endocarditis (SABE):** Viridans streptococci are the most common cause of SABE. The commensal viridans streptococci (e.g. *S. mitis*—*S. sanguinis* group) in the oral cavity can enter blood to cause transient bacteremia while chewing, tooth brushing and dental procedures that can account for the predilection of these organisms to cause endocarditis
- ❖ **Dental caries:** It is mainly caused by *S. mutans* which breaks down dietary sucrose to acid and dextrans with the help of an enzyme glucosyl transferase. Acid damages the dentine, while adhesive dextran binds together with food debris, mucus, epithelial cells and bacteria to produce **dental plaques**
- ❖ **In cancer patients:** Viridans streptococci can cause prolonged bacteremia among neutropenic patients undergoing cancer chemotherapy
- ❖ ***S. milleri* group** (includes *S. intermedius*, *S. anginosus*, and *S. constellatus*): Produce suppurative infections, particularly brain abscess and empyema.

**Laboratory Diagnosis**

- ❖ On Gram stain, they appear as gram-positive cocci arranged in long chains (Fig. 28.2A)
- ❖ They produce minute α-hemolytic green-colored (rarely non-hemolytic) colonies on blood agar ("*viridis*" means green, Fig. 28.2B)





**Figs 28.2A and B:** Viridans streptococci: **A.** Gram-positive cocci in long chains; **B.** α-hemolytic colonies on blood agar.

Source: Department of Microbiology, Pondicherry Institute of Medical Sciences, Puducherry (with permission).

- ❖ They can be differentiated from *Streptococcus pneumoniae* (which is also α-hemolytic) by a number of tests such as resistant to optochin and insoluble in bile (Chapter 61)
- ❖ Accurate species identification is made by automated methods such as MALDI-TOF.

#### TREATMENT

#### Viridans streptococci

Most strains are susceptible to penicillin. Resistant isolates may be treated with penicillin plus gentamicin (for low level resistance) or ceftriaxone/vancomycin (for high resistance).

#### Nutritionally Variant Streptococci

*Abiotrophia* and *Granulicatella* species are known as nutritionally variant streptococci as they require vitamin B (pyridoxal) in the culture medium for their growth. Earlier, they were grouped along with viridans streptococci.

- ❖ **Manifestation:** They are normal inhabitants of the oral cavity and similar to other oral commensals, they can also cause endocarditis
- ❖ **Diagnosis:** They can be recovered in automated blood cultures such as BacT/ALERT. Multiple blood cultures and prolonged incubation may be necessary. They are gram-positive cocci and species identification can be made by automated identification systems such as MALDI-TOF.
- ❖ **Treatment:** Combination therapy with penicillin/ampicillin/ceftriaxone plus gentamicin is recommended for IE cases.

#### *S. gallolyticus* Endocarditis

*S. gallolyticus* (formerly *S. bovis*) is a group D *Streptococcus*, found as a commensal in intestine of animals. In humans, it occasionally causes bacteremia, subacute endocarditis, and also associated with colorectal cancer or polyps. Treatment is same as for viridans streptococcal IE cases. (Chapter 52).

#### HACEK Endocarditis

HACEK is an abbreviation used to represent a group of highly fastidious, slow-growing, capnophilic, gram-negative bacteria, that normally reside in the oral cavity as commensal, but occasionally have been associated with local infections of the mouth and systemic infections such as bacterial endocarditis. Species belonging to this group include:

- ❖ *Haemophilus parainfluenzae*
- ❖ *Aggregatibacter* species: *A. actinomycetemcomitans*, and *A. aphrophilus*

- ❖ *Cardiobacterium hominis*
- ❖ *Eikenella corrodens*
- ❖ *Kingella kingae*.

HACEK endocarditis accounts for 3% of total IE cases.

- ❖ Typically has a subacute course
- ❖ Occurs in patients with preexisting valvular defects or those undergoing dental procedures
- ❖ The aortic and mitral valves are most commonly affected.

#### Clinical Manifestations

- ❖ ***Haemophilus parainfluenzae*:** It is a commensal in mouth and throat
  - Occasionally, it can be an opportunistic pathogen causing endocarditis, conjunctivitis, abscesses, genital tract infections and bronchopulmonary infections in patients with cystic fibrosis
  - It can be differentiated from *H. influenzae* either by its growth requirement (requires only factor V, but not X), or by automated identification systems such as MALDI-TOF or VITEK.
- ❖ ***Aggregatibacter actinomycetemcomitans*:** Formerly called as *Actinobacillus actinomycetemcomitans*
  - It is the most common member of HACEK to cause endocarditis
  - It can also be isolated from soft tissue infections and abscesses associated with *Actinomyces israelii*
  - Rarely, it can cause periodontitis, brain abscess, meningitis and endophthalmitis.
- ❖ ***Aggregatibacter aphrophilus* and *A. paraphrophilus*:** Earlier members of *Haemophilus*, now are renamed under genus *Aggregatibacter*
  - They are commensals of mouth and occasionally cause endocarditis, head and neck infections, invasive bone and joint infections
  - *A. aphrophilus* requires only factor X, whereas *A. paraphrophilus* requires only factor V.
- ❖ ***Cardiobacterium hominis*:** It frequently affects the aortic valve. It is also associated with arterial embolization, immune complex glomerulonephritis or arthritis
- ❖ ***Eikenella corrodens*:** Apart from endocarditis, it can also occasionally cause skin and soft tissue infections. The name 'corrodens' refers to the characteristic **pitting or corroded colonies** on blood agar
- ❖ ***Kingella kingae*:** In addition to endocarditis, it can also cause infections of bones, joints and tendons.

#### Laboratory Diagnosis

The laboratory diagnosis of HACEK endocarditis is as follows:

- ❖ **Culture:** Blood cultures are performed on automated systems such as BacT/ALERT
  - As they are highly fastidious, require multiple blood cultures, and prolonged incubation up to 1 week
  - They are capnophilic, growth is optimum in presence of 5–10% of CO<sub>2</sub>
  - Identification is made by automated systems such as MALDI-TOF.
- ❖ **Molecular methods:** Simultaneous detection of HACEK members from clinical specimens is possible by

performing (i) broad-range bacterial PCR targeting 16S rRNA gene followed by sequencing; (ii) multiplex PCR or multiplex real-time PCR.

### TREATMENT

#### HACEK endocarditis

The prognosis of HACEK endocarditis is good.

- ❑ Ceftriaxone (2 g/day) is the drug of choice for most of the HACEK organisms except *Eikenella corrodens* where ampicillin is indicated
- ❑ Quinolones are given if the strain is a  $\beta$ -lactamase producer
- ❑ Duration of treatment: Antibiotics are given for 4 weeks for native valve endocarditis and 6 weeks for prosthetic-valve endocarditis.

## ■ OTHER INFECTIONS OF CVS

### Myocarditis

Myocarditis refers to inflammation of the myocardium, which is clinically manifested by chest pain, arrhythmias, or congestive heart failure. It is rapidly progressive and often fatal. It can be caused by both infectious and non-infectious etiology. The infectious etiological agents include:

- ❖ **Viruses** are the most common agents; most common being Coxsackievirus B, followed by adenoviruses, parvovirus B19, human herpesvirus 6, and dengue viruses
- ❖ **Parasitic agent** such as *Trypanosoma cruzi*, the agent of Chagas' disease
- ❖ **Bacterial agent**: It is rarely caused by bacteria, as a result of bacteremia, direct extension from a contiguous focus, or a bacterial toxin.

### Pericarditis

Inflammation of the pericardium is clinically presented by one or more of the following manifestations—chest pain, pericardial friction rub, and pericardial effusion. It can be caused by both infectious and non-infectious etiology. The infectious etiologic agents include:

- ❖ **Viruses** are the most common agents; such as Coxsackievirus B (most common cause), Echovirus, Adenovirus, HIV and others
- ❖ **Bacteria** may rarely cause purulent pericarditis, usually as a complication of pneumonia due to *S. aureus*, *H. influenzae*, meningococcus and pneumococcus
- ❖ *M. tuberculosis* can cause pericarditis, usually as a complication of pulmonary tuberculosis.

### Infections of Blood Vessels

Infections of blood vessels include the following conditions:

- ❖ **Mycotic aneurysm**: Refers to the inflammatory damage of an arterial wall; leading to a bulging, that can eventually rupture. The common etiologic agents are streptococci and staphylococci
- ❖ **Device-related infections**: These include infections of various devices inserted in the blood vessels such as central line and peripheral IV cannula
- ❖ **CRBSI** (Catheter-related bloodstream infection): It is a major healthcare-associated infection, discussed in detail in Chapter 22.

❖ **Suppurative thrombophlebitis (STP)**: Refers to inflammation of a vein wall, that occurs frequently in hospitalized patients after 3–4 days of IV cannulation (e.g. veinflam), which gets colonized by the organisms present on the patient's skin or hands of the healthcare workers

- **Common etiology**: *S. aureus*, members of order Enterobacterales, yeasts (*Candida*) etc.
- **Lemierre's syndrome**: It is a thrombophlebitis of the internal jugular vein—caused primarily by anaerobic organism *Fusobacterium necrophorum*, following a recent oropharyngeal infection.

## ■ ACUTE RHEUMATIC FEVER

Acute rheumatic fever (ARF) is a multisystem disease that occurs in people previously affected with streptococcal (group A) sore throat, as a result of an autoimmune reaction. Although ARF may involve many parts of the body, almost all the manifestations resolve completely; except the cardiac valvular damage, which is called as rheumatic heart disease (RHD).

Group A *Streptococcus* (*S. pyogenes*) principally causes infections of skin and soft tissues and is discussed in Chapter 52.

### Pathogenesis

Primary ARF is mainly a disease of children (5–14 years). However, recurrent episodes of ARF are more common in young adults. There is no gender association for ARF, but RHD more commonly affects females.

- ❖ **URTI**: ARF occurs following upper respiratory tract infection with group A streptococci (usually by M-serotypes 1, 3, 5, 6, 14, 18, 19, 24, 27, and 29)
- ❖ **Genetic predisposition**: People with HLA-DR7 and HLA-DR4 appear to be more susceptible
- ❖ **Autoimmune theory**: Pathogenesis is based on the theory of **molecular mimicry**—the antibodies targeted against streptococcal antigens (M protein) cross-react with human tissue antigens (e.g. heart and joint). These cross-reactive antibodies bind to valvular endothelium, leading to damage to the heart valves (Table 52.3, Chapter 52).

### Clinical Manifestations

The clinical manifestations usually appear after a period of ~3 weeks following precipitating group A streptococcal infection. The prior streptococcal infection may be either subclinical (more common) or presents as sore throat.

Acute rheumatic fever affects heart, joints, skin and brain. The common manifestations in the order of frequency include:

- ❖ **Migrating polyarthrititis**: It is the most common manifestation. Joints become hot, swollen, red, and/or tender, which moves from one joint to another over a period of hours. Most commonly affected joints are the knees, ankles, hips, and elbows
- ❖ **Pancarditis**, affecting endocardium, pericardium, or myocardium

- ❖ **Subcutaneous nodules:** Occur as painless, small, mobile lumps beneath the skin overlying bony prominences, particularly of the hands, feet, and elbows
- ❖ **Chorea (Sydenham's):** It is an abnormal involuntary movement disorder, mainly affecting head and limbs
- ❖ **Erythema marginatum:** They are pink macular rashes that appear and disappear before the examiner's eyes.

### Diagnosis of ARF (Jones Criteria)

The diagnosis of ARF is made based on diagnostic criteria known as revised Jones criteria (2015). It is based on the presence of a combination of typical clinical features together with ECG and laboratory findings (ESR, CRP) (Table 28.4).

Elevated anti-streptolysin O (ASO) titer was a part of Jones criteria 1992; has been removed from the revised Jones criteria (2015), as it is not a consistent marker for recent streptococcal infection.

### TREATMENT

#### Rheumatic fever

Penicillin is the drug of choice; can be given orally (as penicillin V or amoxicillin for 10 days) or intramuscularly as single dose of 1.2 million units of benzathine penicillin G. Supportive treatment (e.g. aspirin) should be given for arthritis, arthralgia, and fever.

### Prevention

#### Primary Prevention

It includes timely and complete treatment of group A streptococcal sore throat with antibiotics (penicillin) within 9 days of sore throat onset, which will prevent almost all cases of ARF.

#### Secondary Prevention

The mainstay of controlling ARF and RHD is secondary prevention. Patients with ARF are at much higher risk of developing recurrent ARF. Therefore, long-term penicillin prophylaxis is indicated to prevent recurrences. The drug of choice for secondary prophylaxis is benzathine penicillin G (1.2 million units, or 600,000 units if  $\leq 27$  kg) given every 4 weeks. In case of penicillin allergy, erythromycin (250 mg, twice a day) can be given as an alternative. The duration depends upon underlying carditis.

**Table 28.4: Diagnostic criteria for rheumatic fever—modified Jones criteria (2015).**

Major criteria	
Low-risk population*	Moderate- and high-risk populations
Carditis (clinical or subclinical)	Carditis (clinical or subclinical)
Arthritis—only polyarthritis	Arthritis—monoarthritis or polyarthritis
	Polyarthralgia
Chorea	Chorea
Erythema marginatum	Erythema marginatum
Subcutaneous nodules	Subcutaneous nodules
Minor criteria	
Low-risk population*	Moderate- and high-risk populations
Polyarthralgia	Monoarthralgia
Hyperpyrexia ( $\geq 38.5^{\circ}\text{C}$ )	Hyperpyrexia ( $\geq 38.0^{\circ}\text{C}$ )
ESR $\geq 60$ mm/h and/or CRP $\geq 3.0$ mg/dL	ESR $\geq 30$ mm/h and/or CRP $\geq 3.0$ mg/dL
Prolonged PR interval	Prolonged PR interval
Diagnostic criteria	
Initial ARF	Two major or One major + two minor
Recurrent ARF (with a reliable past history of ARF/RHD)	Two major or One major + two minor or Three minor criteria

Abbreviations: ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ARF, acute rheumatic fever; RHD, rheumatic heart disease.

\*Low risk is defined as an ARF incidence  $< 2$  per 100,000 school-aged children (5–14 years old) per year, or an all-age prevalence of RHD of  $\leq 1$  per 1,000 population per year.

- ❖ **ARF without carditis:** For 5 years after the last attack or 21 years of age (whichever is longer)
- ❖ **ARF with carditis but no residual valvular disease:** For 10 years after the last attack, or 21 years of age (whichever is longer)
- ❖ **ARF with persistent valvular disease:** For 10 years after the last attack, or 40 years of age (whichever is longer) or sometimes lifelong prophylaxis.

## EXPECTED QUESTIONS

### I. Write essay on:

1. A 75-year-old man was hospitalized with fever ( $101^{\circ}\text{F}$ ), severe back-pain and weakness in lower limbs. On examination, few non-tender, small erythematous nodular lesions on soles were seen. Echocardiogram showed valvular vegetations on mitral valve. Two pairs of blood cultures were sent which subsequently were positive for viridans streptococci. The patient was immediately started on benzyl penicillin.
  - a. What is the probable clinical diagnosis?
  - b. What are the typical etiological agents?
  - c. Describe the diagnostic criteria used for this condition.
  - d. How will you collect specimen for this clinical condition?

#### Case Study Infective Endocarditis

2. A 7-year-old female child presented to the cardiology OPD with swollen, red, and/or tender joints, which migrates from one joint to another (knees, ankles, hips, and elbows) over a period of hours. The child was having an abnormal gait. She also complained of painless, small, mobile lumps beneath the skin overlying bony prominences, particularly of the hands, feet, and elbows. On auscultation, murmur was heard over the mitral valve area. ECG showed prolongation of P-R interval. On inquiry, it was found that the child had an episode of sore throat 3 weeks back.
  - a. What is the probable clinical diagnosis?
  - b. Describe the diagnostic criteria used for this condition.
  - c. How will you prevent the recurrence of such episodes?

#### Case Study Acute Rheumatic Fever



**JAYPEE  
BROTHERS**

ISBN 978-93-5696-332-0



9 789356 963320